Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.36
AU$0.02(4.17%)
At close: 4:00 PM EDT
AU$0.36
AU$0.02(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.73
Previous CloseN/A
Volume134.82K
Average Volume (3M)154.69K
Market Cap
AU$113.04M
Enterprise ValueAU$198.04
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding305,520,080
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$4.80M
Bulls Say, Bears Say
Bulls Say
Broad-spectrum Anti-infective PipelineRecce's portfolio targets broad-spectrum antibacterial indications including sepsis and skin infections, addressing antimicrobial resistance. A differentiated clinical-stage pipeline with IV, oral and topical formulations supports durable demand and multiple commercialization pathways if clinical success is achieved.
Improving Free Cash Flow GrowthA 51.97% rise in free cash flow growth indicates improving cash generation efficiency versus prior periods. Sustained FCF gains can extend clinical development runway, reduce near-term dilution needs, and strengthen negotiating leverage for partnerships or licensing over the medium term.
Positive Return On EquityDespite balance sheet stress, a 7.02% ROE suggests management can extract returns from the equity base and advance assets efficiently. This operational efficiency metric, if maintained, supports capital deployment effectiveness through development milestones.
Bears Say
Declining RevenueA 21.73% revenue decline is a durable structural concern: shrinking top-line reduces internal funding for R&D, tightens runway, and increases reliance on external financing. For a clinical-stage biotech, sustained revenue contraction weakens strategic flexibility and partnership leverage.
Severe Negative MarginsVery large negative margins reflect heavy losses relative to revenues and persistent cash burn. Over months, such magnitude of losses is likely to require repeated financing or partnerships, raising dilution risk and potentially delaying development timelines if funding terms worsen.
Negative Equity And High LeverageNegative equity and a -3.53 debt-to-equity ratio create structural financing and solvency risk. This undermines flexibility to raise capital on favorable terms, complicates partnering or licensing negotiations, and increases the likelihood of covenant or refinancing stress over the medium term.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.35 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$113.04M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 22 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 305,520,080 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RCE Sentiment 82%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Technical Analysis
Biotron
―
Starpharma Holdings Limited
―
Immuron Limited
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―